BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways

PLoS One. 2014 May 7;9(5):e96816. doi: 10.1371/journal.pone.0096816. eCollection 2014.

Abstract

Bone morphogenetic protein 9 (BMP9), a member of TGF-β superfamily, is reported to inhibit the growth and migration of prostate cancer, osteosarcoma and triple-negative MDA-MB-231 breast cancer cells. However, little is known about the effect of on the biological behaviors of HER2-positive SK-BR-3 breast cancer cells and the underlying mechanisms. This study aimed to investigate the effects of BMP9 on the proliferation and metastasis of SK-BR-3 cells with BMP9 over-expression or BMP9 down-regulated expression. Results indicated that exogenously expressed BMP9 inhibited the proliferation and metastasis of SK-BR-3 cells while decreased endogenous BMP9 expression in SK-BR-3 cells promoted the proliferation and migration of breast cancer cells in vitro and in vivo. In SK-BR-3 cells with BMP9 over-expression, the phosphorylation of HER2, ERK1/2 and AKT was markedly suppressed and the HER2 expression decreased at both mRNA and protein levels, while opposite results were observed in SK-BR-3 cells with BMP9 knock down. When the phosphorylation of ERK1/2 and PI3K/AKT was inhibited by PD98059 and LY294002, respectively, the decreased proliferation and invasion induced by BMP9 knock down were eliminated. These findings suggest that BMP9 can inhibit the proliferation and metastasis of SK-BR-3 cells via inactivating ERK1/2 and PI3K/AKT signaling pathways. Thus, BMP9 may serve as a useful agent in the treatment of HER-2 positive breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / genetics
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Cell Proliferation / genetics
  • Female
  • Gene Expression Regulation, Neoplastic / genetics
  • Growth Differentiation Factor 2
  • Growth Differentiation Factors / genetics*
  • Growth Differentiation Factors / metabolism
  • Humans
  • MAP Kinase Signaling System / genetics
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Oncogene Protein v-akt / genetics*
  • Oncogene Protein v-akt / metabolism
  • Phosphatidylinositol 3-Kinases / genetics*
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Messenger / biosynthesis
  • Receptor, ErbB-2 / genetics

Substances

  • GDF2 protein, human
  • Growth Differentiation Factor 2
  • Growth Differentiation Factors
  • RNA, Messenger
  • Receptor, ErbB-2
  • Oncogene Protein v-akt

Grants and funding

This work was supported by National Natural Science Foundation of China (81172017) and National Basic Research Program of China (973 Program, 2011CB707906). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.